Neoplasms by Site study with WXS data on dbGaP (37 participants)

phs003019 — Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the    Oral PARP Inhibitor Olaparib in Patients with Recurrent Triple    Negative Breast Cancer or High Grade Serous Ovarian Cancer

<p>We analyzed massive parallel sequence data from patients with breast and ovarian cancer and identified single base substitution mutational signature 3 (Sig3) - extracted using SigMA - as a biomarker of homologous recombination deficiency (HRD) and predictive for response to PARP inhibitors. Participants were patients enrolled in clinical trials as 2 independent datasets: (1) high-grade serous ovarian cancer and triple-negative breast cancer (TNBC) from a Phase 1b trial of the PARP inhibitor olaparib in combination with the PI3K inhibitor buparlisib (BKM120) (<a href="https://clinicaltrials.gov/ct2/show/NCT01623349?cond=NCT01623349">NCT01623349</a>), and (2) TNBC patients who received neoadjuvant olaparib in the Phase II PETREMAC trial (<a href="https://clinicaltrials.gov/ct2/show/NCT02624973">NCT02624973</a>).</p>

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the    Oral PARP Inhibitor Olaparib in Patients with Recurrent Triple    Negative Breast Cancer or High Grade Serous Ovarian Cancer